Experimental combo for tough cancers shows early promise, but trial halted

NCT ID NCT02298153

Terminated Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested a combination of two drugs—atezolizumab (an immunotherapy) and epacadostat (an oral drug that helps the immune system attack cancer)—in 29 patients with advanced lung or bladder cancer that had already been treated with chemotherapy. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atezolizumab (immunotherapy) and epacadostat (oral drug that boosts immune response)
What this could lead to: If successful, this combination could offer a new treatment option for advanced lung and bladder cancers that have stopped responding to standard chemotherapy.
What could go wrong: This was a very early (Phase 1) safety study with only 29 participants, and it was terminated early, so we don't know if the combination works or is safe long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (NON-SMALL CELL LUNG CARCINOMA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma urethra transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC (NON-SMALL CELL LUNG CARCINOMA) UC (UROTHELIAL CANCER)

Contacts and locations

Locations

Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Harvard-Mass General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Pinnacle Oncology Hematology

Scottsdale, Arizona, 85258, United States
University of Washington

Seattle, Washington, 98109, United States
Yale University

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.